Status:
UNKNOWN
A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor Mark
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Brief Summary
The aims of this study were divided into three parts: 1. To evaluate the sensitivity and specificity of GP73 for the diagnosis of hepatitis B related HCC. Established the standard of GP73 in normal p...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- A group of patients with no history of liver disease, alcohol consumption less than 40g a week, and no risk factors for viral hepatitis were enrolled from the General Internal Medicine clinics. All subjects in this control group were documented to have normal liver biochemistry.
- Consecutive patients with HCC and patients with HBV \& HCV that were age, gender, and race/ethnicity matched to the HCC patients were enrolled from the Liver Clinic during this period. The diagnosis of HCC was made by histopathology, and if histopathology was not available by two imaging modalities (ultrasound \[US\], magnetic resonance imaging \[MRI\], or computed tomography) showing a vascular enhancing mass \>2cm. HBV infection status was based on hepatitis B surface antigen (HBsAg). HCV infection status was based on serum HCV antibody and HCV-RNA positive.
Exclusion
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00902902
Start Date
January 1 2008
End Date
July 1 2009
Last Update
May 15 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Chicago
Chicago, Illinois, United States, 60637